Atara Biotherapeutics Lands $13,500,000 Series B Round

  • Feed Type
  • Date
    1/10/2014
  • Company Name
    Atara Biotherapeutics
  • Mailing Address
    2659 Townsgate Road Thousand Oaks, CA 91361
  • Company Description
    Our mission is to develop novel treatment options for patients with severe and life-threatening conditions that have been underserved by scientific innovation. We are investigating therapies targeting unique pathways to pause or reverse patients’ underlying diseases.
  • Website
    http://www.atarabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $13,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months. PINTA 745 is a myostatin inhibiting peptibody in Phase 2 development as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.
  • M&A Terms
  • Venture Investor
    Alexandria Real Estate Equities
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Celgene
  • Venture Investor
    DAG Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    The Baupost Group

By posting a comment, you agree to our terms and conditions.